Latest Insider Transactions at Enanta Pharmaceuticals Inc (ENTA)
This section provides a real-time view of insider transactions for Enanta Pharmaceuticals Inc (ENTA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ENANTA PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ENANTA PHARMACEUTICALS INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,480
+5.35%
|
$38,280
$11.77 P/Share
|
|
Apr 04
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
32,785
-14.66%
|
$2,360,520
$72.08 P/Share
|
|
Apr 04
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
32,785
+16.35%
|
$1,672,035
$51.81 P/Share
|
|
Apr 01
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
50,559
-32.21%
|
$3,589,689
$71.04 P/Share
|
|
Apr 01
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50,559
+18.29%
|
$1,820,124
$36.65 P/Share
|
|
Mar 21
2022
|
Bruce L A Carter Director |
SELL
Open market or private sale
|
Direct |
6,000
-56.77%
|
$408,000
$68.03 P/Share
|
|
Mar 21
2022
|
Bruce L A Carter Director |
BUY
Exercise of conversion of derivative security
|
Direct |
6,000
+50.0%
|
$150,000
$25.58 P/Share
|
|
Mar 02
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,481
-26.3%
|
$873,670
$70.07 P/Share
|
|
Mar 02
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,481
+20.82%
|
$536,683
$43.46 P/Share
|
|
Mar 01
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
24,339
-20.57%
|
$1,703,730
$70.66 P/Share
|
|
Mar 01
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
24,339
+29.09%
|
$1,046,577
$43.46 P/Share
|
|
Feb 14
2022
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,355
-0.33%
|
$146,010
$62.49 P/Share
|
|
Feb 14
2022
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
8,028
+0.56%
|
-
|
|
Feb 14
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
958
-1.62%
|
$59,396
$62.49 P/Share
|
|
Feb 14
2022
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+2.51%
|
-
|
|
Feb 14
2022
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
953
-0.28%
|
$59,086
$62.49 P/Share
|
|
Feb 14
2022
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+0.44%
|
-
|
|
Feb 14
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
954
-2.65%
|
$59,148
$62.49 P/Share
|
|
Feb 14
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+4.05%
|
-
|
|
Feb 14
2022
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
957
-2.03%
|
$59,334
$62.49 P/Share
|
|
Feb 14
2022
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,034
+3.12%
|
-
|
|
Feb 14
2022
|
Tara Lynn Kieffer Chief Product Strategy Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
552
-6.56%
|
$34,224
$62.49 P/Share
|
|
Feb 14
2022
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,616
+8.83%
|
-
|
|
Feb 14
2022
|
Brendan Luu Chief Business Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
489
-5.95%
|
$30,318
$62.49 P/Share
|
|
Feb 14
2022
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,412
+7.97%
|
-
|
|
Jan 15
2022
|
Jay R. Luly President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,063
+1.4%
|
$110,693
$11.77 P/Share
|
|
Jan 11
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
12,536
-27.59%
|
$877,520
$70.13 P/Share
|
|
Jan 11
2022
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,536
+12.39%
|
$451,296
$36.73 P/Share
|
|
Dec 01
2021
|
Jay R. Luly President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,944
-0.28%
|
$169,128
$87.68 P/Share
|
|
Dec 01
2021
|
Paul J Mellett Chief Fin. & Admin Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-0.98%
|
$48,459
$87.68 P/Share
|
|
Dec 01
2021
|
Yat Sun Or Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-0.16%
|
$48,459
$87.68 P/Share
|
|
Dec 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,523
-4.72%
|
$1,176,501
$87.45 P/Share
|
|
Dec 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,523
+13.34%
|
$608,535
$45.99 P/Share
|
|
Dec 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
842
-2.5%
|
$73,254
$87.68 P/Share
|
|
Dec 01
2021
|
Nathaniel S. Gardiner Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
557
-0.93%
|
$48,459
$87.68 P/Share
|
|
Nov 19
2021
|
Jay R. Luly President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
25,700
+3.53%
|
-
|
|
Nov 19
2021
|
Paul J Mellett Chief Fin. & Admin Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+10.73%
|
-
|
|
Nov 19
2021
|
Yat Sun Or Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+1.97%
|
-
|
|
Nov 19
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+16.77%
|
-
|
|
Nov 19
2021
|
Nathaniel S. Gardiner Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+10.21%
|
-
|
|
Nov 19
2021
|
Tara Lynn Kieffer Chief Product Strategy Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+50.0%
|
-
|
|
Nov 19
2021
|
Brendan Luu Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
6,800
+50.0%
|
-
|
|
Nov 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
9,547
-9.14%
|
$811,495
$85.18 P/Share
|
|
Nov 01
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,547
+20.74%
|
$458,256
$48.52 P/Share
|
|
Oct 11
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
4,047
-13.06%
|
$283,290
$70.34 P/Share
|
|
Oct 11
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,047
+11.55%
|
$174,021
$43.46 P/Share
|
|
Oct 08
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
13,453
-33.3%
|
$941,710
$70.09 P/Share
|
|
Oct 08
2021
|
Nathalie Adda Sr. VP & Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,453
+24.98%
|
$578,479
$43.46 P/Share
|
|
Sep 15
2021
|
Jay R. Luly President and CEO |
SELL
Open market or private sale
|
Direct |
4,516
-0.66%
|
$266,444
$59.06 P/Share
|
|
Jan 26
2021
|
Yat Sun Or Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,693
+1.38%
|
$164,316
$12.57 P/Share
|